Skip to main content
ResearchTreatments

FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

By June 21, 2021November 7th, 2021No Comments

*May 2021*

The U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Rybrevant today.

Read more.